Senior Consultant, Surgical Oncology, Fortis Hospital, Noida
Part 9 of 9 in Diagnosis and Management of Breast Cancer
Chemotherapy, Hormonal and Targeted Therapy: Regimens and Managing Metastatic Disease
November 17, 2024
Beyond surgery and radiation, systemic treatment covers chemotherapy, hormonal therapy, targeted therapy, and immunotherapy, sequenced according to the same receptor biology that governs surgical timing.
Adjuvant versus neoadjuvant, and the standard regimen
Nearly all early breast cancer patients require chemotherapy, and the standard of care is anthracycline-based, typically given over six cycles. A subset of patients with favorable disease characteristics, particularly small, node-negative tumors, may safely avoid chemotherapy altogether. Triple-negative and HER2-positive tumors, even when operable, receive neoadjuvant chemotherapy before surgery, while hormone-positive tumors receive hormonal therapy alongside surgery-first sequencing, and HER2-positive disease adds targeted therapy on top of chemotherapy.
Managing metastatic breast cancer
In metastatic disease, chemotherapy is generally the primary treatment, chosen according to ER, PR, and HER2 status, and can be combined with hormonal therapy where appropriate. A typical course runs six to eight cycles, extending to around 18 to 20 cycles of HER2-directed therapy in HER2-positive disease. Roughly 30 to 35% of metastatic patients respond well enough that even the primary tumor and metastatic sites can sometimes be addressed surgically. If a patient remains symptomatic after eight cycles, second- or third-line chemotherapy, immunotherapy, and CDK4/6 inhibitors are the next options, with next-generation sequencing of the tumor used to identify which targeted drug is likely to work for that specific patient.
This article is based on a Jivo Masterclass session conducted by Dr. Jalaj Baxi, Senior Consultant, Surgical Oncology, Fortis Hospital, Noida. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording
Looking for a breast cancer consultation or a second opinion? Get in touch with the Jivo team
This guide is based on a live Jivo Masterclass: Dr. Jalaj Baxi taught doctors across Africa on November 17, 2024.
FROM THE LIVE Q&A
Moderator
If a patient remains symptomatic after eight cycles of chemotherapy, what other treatment options are available?
Dr. Jalaj Baxi
Immunotherapy can be added, and second-line or third-line chemotherapy regimens are available, including CDK4/6 inhibitors. Next-generation sequencing of the tumor helps identify which newer targeted drugs are likely to be effective for that specific patient.
Frequently Asked Questions
Why do many patients' health seem to deteriorate immediately after a breast cancer diagnosis?▼
This is largely psychological rather than driven by the disease itself, a kind of cancer phobia that sets in once the diagnosis is given, where the patient loses a sense of control over their own life and fears dying early or being treated inadequately. Educating patients about their specific disease and realistic treatment outcomes helps restore the sense that there is still a fight to be had, which improves how they cope.
In what situations is prophylactic mastectomy appropriate in early-stage breast cancer?▼
Only in patients with a genetically determined risk, specifically those who test positive for BRCA1 or BRCA2 mutations. BRCA testing itself is only done when there is a family history of breast cancer.
What modalities help prevent reactions to anti-cancer drugs and reduce mortality during chemotherapy?▼
Mortality in chemotherapy is a fairly rare event, and when it happens it is almost always due to bone marrow suppression. The key is giving chemotherapy under close supervision so that this suppression is caught early, since early detection is what actually prevents mortality.
How does surgery compare with radiotherapy for local control in advanced-stage breast cancer?▼
Radiotherapy is used only when surgery is not possible. If chemotherapy shrinks the tumor enough that surgery becomes feasible, surgery should be done. Radiotherapy has very few indications in advanced disease, so a direct comparison between the two is not really meaningful in this setting.
What are the natural causes of breast cancer?▼
There is no true natural cause; the underlying event is always a gene mutation. About 80% of cases are sporadic mutations with no identifiable cause, while 10 to 15% are genetic or familial. Smoking, alcohol, and tobacco all contribute to mutation risk generally and should be avoided, though this applies to cancer as a whole rather than being specific to breast cancer.
What is the standard chemotherapy regimen for early breast cancer?▼
Anthracycline-based chemotherapy, typically given over six cycles, is the standard of care, though a subset of patients with small, node-negative, favorable-biology tumors may safely avoid chemotherapy altogether.
What options exist if metastatic breast cancer doesn't respond after eight cycles of chemotherapy?▼
Second-line or third-line chemotherapy regimens, immunotherapy, and CDK4/6 inhibitors are the next options, guided by next-generation sequencing of the tumor to identify which targeted drug is likely to be effective.
In This Series: Diagnosis and Management of Breast Cancer
- 1.Diagnosis and Management of Breast Cancer
- 2.How Breast Cancer Presents: Warning Signs Every Referring Doctor Should Know
- 3.The Triple Assessment: Clinical, Radiological and Pathological Workup
- 4.Biopsy Techniques and Receptor Testing in Breast Cancer
- 5.Staging Breast Cancer and How Tumor Biology Drives Treatment Sequencing
- 6.Breast Conservation Surgery vs Mastectomy: When Each Is Appropriate
- 7.Axillary Management: Lymph Node Dissection vs Sentinel Node Biopsy
- 8.Radiation Therapy After Breast Cancer Surgery: When It's Needed
- 9.Chemotherapy, Hormonal and Targeted Therapy: Regimens and Managing Metastatic Disease